EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Headache in individuals undergoing hormone therapy for gender transition: A cross‐sectional, observational study

Lucia Jimena Zavala iD, Andreina Gil Ramirez, Kjersti Grøtta Vetvik, Rigmor Højland Jensen iD, Anders Hougaard iD

Headache: The Journal of Head and Face Pain · 2025

DOI: 10.1111/head.15076 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Headache: The Journal of Head and Face Pain, 2025. Verfasst von Lucia Jimena Zavala und 4 weiteren Autor:innen. Beteiligte Einrichtung: Danish Headache Center, Department of Neurology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Testosterone, Estrogens, Migraine Disorders, Transgender Persons. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To assess the prevalence, frequency, and characteristics of headache disorders in transgender individuals receiving gender‐affirming hormone therapy (GAHT), and to explore the relationship between GAHT and headache pathophysiology. We hypothesized that estrogen‐based GAHT would be associated with increased risk of headache, particularly migraine, whereas testosterone‐based GAHT would be associated with reduced headache burden.

Background

Migraine is a highly disabling headache disorder that disproportionately affects cisgender women, with hormonal fluctuations playing a key role in its pathophysiology. Despite extensive research in cisgender populations, there is a gap in our understanding about the prevalence and characteristics of headache disorders, including migraine, in transgender and nonbinary individuals undergoing GAHT, and there is true urgency to fill this knowledge gap.

Methods

We conducted a cross‐sectional, observational study using an anonymous online survey targeting transgender and nonbinary individuals in Argentina from October 2023 to February 2024. Eligible participants were aged ≥18 years and receiving GAHT. The validated Migraine Screen Questionnaire (MS‐Q) was used to identify migraine‐like headaches. Additional items assessed changes in headache characteristics associated with GAHT.

Results

Of 160 participants, 102 (63.7%; 95% confidence interval [CI] 56.1%–70.8%) reported experiencing headaches. Of these, 86.3% (number [ n ] = 88) were receiving testosterone, 11.8% ( n = 12) estrogens, and 2.0% ( n = 2) were receiving other GAHT. Only 24.5% ( n = 24) reported a prior headache diagnosis, including 18 participants (17.6%; 95% CI 11.3%–26.2%) with migraine. Based on the MS‐Q, 46.1% ( n = 47) screened positive for migraine‐like headaches. New headache or worsening of headache was more frequently reported by estrogen users (66.6%) compared to those using testosterone (27.2%). Improvement or resolution of headaches was reported by 26.1% of testosterone users compared to 8.3% of estrogen users.

Conclusion

Estrogen‐based GAHT was associated with a higher proportion of individuals reporting new or worsening headaches, whereas testosterone‐based GAHT was more often associated with headache improvement. These associations underscore the need for further research into how GAHT modulates headache patterns, as well as the high rate of underdiagnosed headache disorders in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TestosteroneEstrogensMigraine DisordersTransgender PersonsGender-Affirming ProceduresHormone Replacement TherapyHeadache DisordersHumansCross-Sectional StudiesFemaleMaleAdultMiddle AgedArgentinaYoung AdultPrevalence

Stichwörter der Autor:innen

gender‐affirming hormone therapymigrainetransgender

Substanzen

TestosteroneEstrogens

Autor:innen und Institutionen

  • Danish Headache Center, Department of Neurology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
  • Department of Biomedical Science, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Department of Neurology, Akershus University Hospital, Lørenskog, Norway.
  • Norwegian Centre for Headache Research (NorHEAD), Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Department of Neurology, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Denmark.

ORCID-Profile: Lucia Jimena Zavala, Rigmor Højland Jensen, Anders Hougaard

Zitieren

APA

Zavala, L. J., Gil Ramirez, A., Vetvik, K. G., Jensen, R. H., & Hougaard, A. (2025). Headache in individuals undergoing hormone therapy for gender transition: A cross‐sectional, observational study. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.15076

Vancouver

Zavala LJ, Gil Ramirez A, Vetvik KG, Jensen RH, Hougaard A. Headache in individuals undergoing hormone therapy for gender transition: A cross‐sectional, observational study. Headache: The Journal of Head and Face Pain. 2025. doi:10.1111/head.15076

BibTeX
@article{Zavala2025,
  author = {Zavala, Lucia Jimena and Gil Ramirez, Andreina and Vetvik, Kjersti Grøtta and Jensen, Rigmor Højland and Hougaard, Anders},
  title = {Headache in individuals undergoing hormone therapy for gender transition: A cross‐sectional, observational study},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2025},
  doi = {10.1111/head.15076}
}
Kostenlos starten →